Verve Therapeutics, Inc. (NASDAQ:VERV) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) have earned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $33.00.

Several equities analysts recently commented on the company. HC Wainwright began coverage on Verve Therapeutics in a research report on Monday, April 8th. They set a “buy” rating and a $15.00 target price for the company. Royal Bank of Canada reissued an “outperform” rating and set a $35.00 price objective on shares of Verve Therapeutics in a report on Wednesday, February 28th. Finally, Stifel Nicolaus lowered their target price on shares of Verve Therapeutics from $56.00 to $40.00 and set a “buy” rating on the stock in a report on Wednesday, April 3rd.

Institutional Investors Weigh In On Verve Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Penserra Capital Management LLC acquired a new position in shares of Verve Therapeutics in the 1st quarter valued at $46,000. PNC Financial Services Group Inc. bought a new position in Verve Therapeutics in the fourth quarter valued at approximately $29,000. Amundi acquired a new position in shares of Verve Therapeutics in the fourth quarter valued at approximately $45,000. Newbridge Financial Services Group Inc. acquired a new position in Verve Therapeutics in the 4th quarter worth $30,000. Finally, Quest Partners LLC bought a new position in Verve Therapeutics during the 4th quarter worth about $34,000. 97.11% of the stock is owned by institutional investors.

Verve Therapeutics Price Performance

NASDAQ VERV opened at $6.74 on Thursday. The company’s fifty day moving average is $12.50 and its two-hundred day moving average is $12.44. Verve Therapeutics has a 52-week low of $6.72 and a 52-week high of $21.42. The firm has a market capitalization of $563.60 million, a price-to-earnings ratio of -2.16 and a beta of 1.70.

Verve Therapeutics (NASDAQ:VERV) last issued its earnings results on Tuesday, February 27th. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.14. Verve Therapeutics had a negative return on equity of 39.33% and a negative net margin of 1,701.70%. The business had revenue of $5.14 million during the quarter, compared to analyst estimates of $3.95 million. As a group, sell-side analysts expect that Verve Therapeutics will post -2.92 earnings per share for the current fiscal year.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.